Cargando…
Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
In closely monitored randomized controlled trials (RCTs), newer P2Y12 agents (ticagrelor and prasugrel) reduced cardiovascular outcomes compared with clopidogrel following percutaneous coronary intervention (PCI) in acute coronary syndrome. However, these RCTs indicated a higher bleeding risk with t...
Autores principales: | Kumar, Arun, Lutsey, Pamela L., St. Peter, Wendy L., Schommer, Jon C., Van't Hof, Jeremy R., Rajpurohit, Abhijeet, Farley, Joel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107606/ https://www.ncbi.nlm.nih.gov/pubmed/36448257 http://dx.doi.org/10.1002/cpt.2806 |
Ejemplares similares
-
Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study
por: Kumar, Arun, et al.
Publicado: (2022) -
Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013–2018
por: Kumar, Arun, et al.
Publicado: (2023) -
Initiation of Statins After Hospitalization for Coronary Heart Disease
por: Ye, Xin, et al.
Publicado: (2007) -
Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention
por: Pham, Phuong-Anh, et al.
Publicado: (2011) -
Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention
por: Ueki, Yasushi, et al.
Publicado: (2019)